Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.38 |
| ▸ | KIF20A | O95235 | 5/20 | 0.38 |
| ▸ | GSK3B | P49841 | 4/20 | 0.37 |
| ▸ | NFATC1 | O95644 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.35 |
| ▸ | CLK1 | P49759 | 3/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22049454 | 0.87 | DYRK1A (0.47) | CCNT1CDK9HASPINDYRK1AGSK3B | |
| SCHEMBL15667411 | 0.74 | CCNT1 (0.62) | HTR6CCNT1CDK9HASPINDYRK1A | |
| Hydrochloric Acid SCHEMBL3967649 | 0.72 | CCNT1 (0.60) | HTR6CCNT1CDK9HASPINDYRK1A | |
| SCHEMBL22050222 | 0.71 | CLK1 (0.30) | CCNT1CDK9HASPINCLK1 | |
| SCHEMBL3898333 | 0.70 | HTR6 (0.59) | HTR6CCNT1CDK9HASPINDYRK1A | |
| SCHEMBL22049684 | 0.69 | TDO2 (0.39) | DYRK1AKIF20ACLK1 | |
| SCHEMBL27569767 | 0.69 | CCNT1 (0.52) | HTR6CCNT1CDK9HASPINPDE10A | |
| SCHEMBL31037775 | 0.68 | HTR6 (0.46) | HTR6HASPINGSK3BKDRFLT3 | |
| SCHEMBL22049700 | 0.68 | ACHE (0.44) | HTR6ACHEPDE10A | |
| SCHEMBL2050489 | 0.67 | HASPIN (0.59) | HTR6CCNT1CDK9HASPINDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | HTR6 469/4885CCNT1 4829/4885CDK9 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.